Pregabalin is a medication used world-wide in the treatment of partial onset seizures, postherpetic neuralgia, diabetic neuropathy, fibromyalgia, spinal cord injury neuropathic pain, and generalized anxiety disorder. The actions of pregabalin are mediated through binding with high affinity to alpha-2-delta proteins, which attenuates calcium influx into presynaptic neurons and thereby blocks the release of neurotransmitters, including the excitatory neurotransmitter l-glutamate.
| Package | Per pill | Total price | Save | Order |
|---|---|---|---|---|
| 150mg × 30 Pills | $1.96 | $58.66 + Bonus - 4 Pills | - | Add to cart |
| 150mg × 60 Pills | $1.56 | $93.70 + Bonus - 4 Pills | $24.00 | Add to cart |
| 150mg × 90 Pills | $1.54 | $138.20 + Bonus - 7 Pills | $37.80 | Add to cart |
| 150mg × 120 Pills | $1.51 | $181.10 + Bonus - 7 Pills | $54.00 | Add to cart |
| 150mg × 240 Pills | $1.40 | $336.93 + Bonus - 11 Pills Free Trackable Delivery | $134.40 | Add to cart |
| Package | Per pill | Total price | Save | Order |
|---|---|---|---|---|
| 75mg × 30 Pills | $1.36 | $40.65 + Bonus - 4 Pills | - | Add to cart |
| 75mg × 60 Pills | $1.10 | $65.70 + Bonus - 4 Pills | $15.60 | Add to cart |
| 75mg × 90 Pills | $1.06 | $95.20 + Bonus - 7 Pills | $27.00 | Add to cart |
| 75mg × 120 Pills | $1.00 | $120.10 + Bonus - 7 Pills | $43.20 | Add to cart |
| 75mg × 240 Pills | $0.92 | $221.93 + Bonus - 11 Pills Free Trackable Delivery | $105.60 | Add to cart |
Spinal cord injury (SCI) is a devastating medical condition affecting 1.2 million people in the United States, with central neuropathic pain being one of the most common and challenging complications to manage. Central neuropathic pain is defined as pain that arises due to a lesion or disease affecting the central nervous system, and it is estimated to affect up to 70% of individuals with SCI.
The current treatment options for central neuropathic pain in patients with SCI include opioids, antiepileptic agents such as gabapentin, antispastic agents such as baclofen or tizanidine, and tricyclic acid. While these treatments may provide some relief, they are often not fully effective and can be associated with significant side effects. Furthermore, due to the complexity of central neuropathic pain, proper assessment and classification tools are essential to improve treatment outcomes.
In order to develop more effective treatment options, a better understanding of the pathophysiology of central neuropathic pain in SCI is needed. Recent research has suggested that changes in the central nervous system, including alterations in neurotransmitter systems and neuroplasticity, may play a role in the development and maintenance of central neuropathic pain. Additionally, psychological factors, such as depression and anxiety, may also contribute to the experience of pain in individuals with SCI.
A combination of approaches, from standard general pain assessments to medically specific questions unique to SCI pathophysiology, is essential for proper assessment and classification of central neuropathic pain in patients with SCI. This includes evaluating the type, location, and intensity of pain, as well as any contributing factors, such as psychological distress or physical impairments.
In addition to pharmacological treatments, complementary, nonpharmacological treatment options such as exercise or acupuncture, interventional treatments, and psychological approaches may also be beneficial. Exercise has been shown to improve physical function and reduce pain in individuals with SCI, while acupuncture may provide temporary pain relief. Psychological interventions, such as cognitive-behavioral therapy and mindfulness-based stress reduction, may help individuals with SCI better manage the emotional and psychological aspects of pain.
A multidisciplinary approach to patient care is crucial in the management and treatment of central neuropathic pain in patients with SCI. This includes collaboration between medical professionals, such as physicians, nurses, and therapists, as well as the involvement of the patient in their own care. A better understanding of the pathophysiology and diagnosis of central neuropathic pain in SCI, in combination with a multidisciplinary approach, will lead to improved management and treatment outcomes for this population.
In summary, while current treatment options for central neuropathic pain in patients with SCI exist, there is a need for more effective and targeted therapies. Proper assessment and classification tools, as well as a better understanding of the pathophysiology, are essential to improve the management and treatment of this complex condition. A multidisciplinary approach, incorporating both pharmacological and nonpharmacological interventions, holds promise for improving the lives of individuals with SCI who experience central neuropathic pain.